

FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1  
Nude Mice Treated with Combination Therapy




FIGURE 10

Weight of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice




FIGURE 11

Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice




FIGURE 12




FIGURE 13




FIGURE 14

Weight of Human Prostate Carcinoma (PC-3)  
in SCID Mice





FIGURE 15

Weight of Human Prostate Carcinoma(DU145)  
in SCID Mice








FIGURE 16



# FIGURE 17

Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice



Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice






FIGURE 18




# FIGURE 19

## A Growth of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice




## B Weight of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice



# FIGURE 20

## Growth of Human Cervix Epitheloid Carcinoma (Hela S3-HU-Resistance) in SCID Mice

A



## Weight of Human Cervix Epitheloid Carcinoma (Hela S3-HU-Resistance) in SCID Mice

B





FIGURE 21

Weight of Human Cisplatin-Resistant Breast Adenocarcinoma  
Implanted at the Fat Pad of SCID Mice




Statistical Analysis: P value  
Saline : Cisplatin 0.0834  
Saline : Taxol <0.0001  
Saline : SEQ ID NO:1 <0.0001  
SEQ ID NO:1 : Cisplatin 0.0007  
SEQ ID NO:1 : Taxol 0.9547


# FIGURE 22

**Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17 SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+ SEQ ID NO:1 (Orthotopical transplant)**

**A**



**B**



**C**






FIGURE 23

Weight of Human Taxol-Resistant Breast Adenocarcinoma  
(MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice

A




B



# FIGURE 24


## Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1) in SCID Mice

A



## Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1) in SCID Mice


B



# FIGURE 25

A

## Growth of Promyelocytic Leukemia HL-60 (Taxol-Resistant) in SCID Mice



B

## Weight of Human Promyelocytic Leukemia HL-60 (Taxol-Resistant) in SCID Mice






FIGURE 26

Growth of Human Multi-Drug Resistance Colon Adenocarcinoma (LS513) in SCID Mice

A




B



Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513) in SCID Mice

C



## FIGURE 27

>gi|4557844|ref|NM\_001034.1| Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA

```
CCCAGGCGCAGCCAATGGGAAGGGTCGGAGGCATGGCACAGCCAATGGGAAGGGCCGGGGCACC AAAAGCC
AATGGGAAGGGCCGGGAGCGCGCGCGCGGGAGATTAAAGGCTGCTGGAGTGAGGGGTGCCCCGTGCAC
CCTGTCCAGCCGCTCCTGTCTGCTGCTCGCTCTGCTTCGCTGCGCCCTCCACTATGCTCTCCCTCCCGTG
TCCCGCTCGCGCCCATCACGGACCCGACAGCTGACAGCTCTCGCCGCTGAAGGGGCTCAGCTTGGTGCA
CAAGGAGAACAACGCGCCGCGCCCTGAGCGGGACCCGCGTCTGCGCCAGCAAGACCGCGAGGAGGATCTTC
CAGGAGCCACGGAGCCGAAAACATAAGCAGCTGCCCGCGCGTGGAGGATGAGCCGCTGCTGAGAGAAA
ACCCCGCGCGCTTTGTCTATCTTCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGC
TTCCTTTTGGACCGCGGAGGAGGTTGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAACCCGAG
GAGAGATATTTTATATCCATGTTCTGGCTTTCTTTGACAGCAAGCGATGGCATAGTAAATGAAAACCTGG
TGGAGCGATTAGCCAAGAAGTTCAGATTACAGAAGCCCGCTGTTTCTATGGCTTCCAAATTGCCATGGA
AAACATACATTCTGAAATGTATAGTCTTCTTATTGACACTTACATAAAGATCCCAAAGAAAGGGAATTT
CTCTTCATGCCATTGAAACGATGCTTGTGTCAAGAAGAAGGCAGACTGGGCCCTTGCGCTGGATTGGGG
ACAAAGAGGCTACCTATGCTGAACTGTTGTAGCCCTTTGCTGCGAGTGGAAGGCATTTCTTTTCCGGTTC
TTTTGCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCCTGGCCCTCACATTTTCTAATGAACCTATT
AGCAGAGATGAGGGTTTACACTGTGATTTTGTCTTGCTGATGTTCAAACACCTGGTACACAAACCATCGG
AGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTCCGATAGAACAGGAGTTCCTCACTGAGGCCCTGGCC
TGTGAAGCTCATTTGGGATGAATTGCACTCTAATGAAGCAATACATTGAGTTTGTGGCAGACAGACTTATG
CTGGAACTGGGTTTTAGCAAGGTTTTACAGAGTAGAGAACCCATTTGACTTTATGGAGAATATTTCACTGG
AAGGAAAGACTAATCTTTGAGAAGAGAGTAGGCCAGTATCAGAGGATGGGAGTGATGTCAAGTCCAAC
AGAGAAATCTTTTACCTTGGATGCTGACTTCTAAATGAAGTGAAGATGTGCCCTTACTTGGCTGATTTTT
TTTTTCCATCTCATAGAAAAATCAGCTGAAGTGTACCAACTAGCCACACCATGAATTGTCCGTAATGT
TCATTAACAGCATCTTTAAAACTGTGTAGCTACCTCACACCAGTCCCTGTCTGTTTATAGTGTCTGGTAGT
ATCACCTTTTGGCAGAAGGCCCTGGCTGGCTGTGACTTACCATAGCAGTGACAATGGCAGTCTTGGCTTTA
AAGTGAGGGGTGACCTTTAGTGAGCTTAGCACAGCGGGATTAAACAGTCCCTTTAACAGCACAGCCAGT
TAAAAGATGCAGCCTCACTGCTTCAACGAGATTTTAATGTTTACTTAAATATAAACCTGGCACTTTACA
AACAAATAAACATTGTTTTGTACTCACGCGCGCGATAATAGCTTGATTTATTTGGTTTTCTACACCAAATA
CATTCTCCTGACCACTAATGGGAGCCAAATTCACAAATTCATAAGTGAATAAGTAAAGTTAACTTGTGTA
GACTAAGCATGTAATTTTAAAGTTTTATTTAATGAATTAAATATTTGTTAACCAACTTTAAAGTCAGT
CCTGTGTATACCTAGATATTAGTCAGTTGGTGCCAGATAGAAGACAGGTTGTGTTTTATCCTGTGGCTT
GTGAGTGTCTGGGATTCTCTGCCCCCTCTGAGTAGAGTGTGTGGGATAAAGGAATCTCTCAGGGCAA
GGAGCTTCTTAAGTTAAATCACTAGAAATTTAGGGGTGATCTGGGCCCTTCATATGTGTGAGAAGCCGTTT
CATTTTATTTCTCACTGTATTTTCTCAACGCTCTGTTGATGAGAAAAAATTCMTGAAGAGTTTTCATAT
GTGGGAGCTAAGGTAGTATTGTAAAATTTCAAGTCATCTTAAACAAAATGATCCACCTAAGATCTTGCC
CCTGTTAAGTGGTGAAATCAACTAGAGGTGGTTCTACAAGTTGTTCAATTCATGTTTGTGTTGGGTGAAG
TAGGTTGTGTGAGTTAATTCATTATATTACTATGTCTGTTAAATCAGAAATTTTATTATCTATGTT
CTTCTAGATTTTACCTGTAGTTCATAAAAAAAAAAAAAAAAAAAAAAAAAA
```

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**